title: Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels.
abstract: BACKGROUND
  Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted inhibitor of the low-density lipoprotein (LDL) receptor and an important regulator of LDL metabolism. Elevated PCSK9 levels have been associated with cardiovascular risk. The purpose of this study was to investigate how ezetimibe and simvastatin, alone and in combination, affect PCSK9 circulating concentrations.
  
  
  METHODS
  A single center, randomized, open-label parallel 3-group study in healthy men (mean age 32±9 years, body mass index 25.7±3.2 kg/m(2)) was performed. Each group of 24 subjects was treated for 14 days with either simvastatin 40 mg/d, ezetimibe 10 mg/d, or with both drugs. Multivariate analysis was used to investigate parameters influencing the change in PCSK9 concentrations under treatment.
  
  
  RESULTS
  The baseline plasma PCSK9 concentrations in the total cohort were 52±20 ng/mL with no statistically significant differences between the groups. They were increased by 68±85% by simvastatin (P = 0.0014), by 10±38% by ezetimibe (P = 0.51) and by 67±91% by simvastatin plus ezetimibe (P = 0.0013). The increase in PCSK9 was inversely correlated with baseline PCSK9 concentrations (Spearman's R = -0.47, P<0.0001) and with the percent change in LDL cholesterol concentrations (Spearman's R = -0.30, P<0.01). In multivariate analyses, only baseline PCSK9 concentrations (β = -1.68, t = -4.04, P<0.0001), percent change in LDL cholesterol from baseline (β = 1.94, t = 2.52, P = 0.014), and treatment with simvastatin (P = 0.016), but not ezetimibe (P = 0.42), significantly influenced changes in PCSK9 levels. Parameters without effect on PCSK9 concentration changes were age, body mass index, body composition, thyroid function, kidney function, glucose metabolism parameters, adipokines, markers of cholesterol synthesis and absorption, and molecular markers of cholesterol metabolism.
  
  
  CONCLUSIONS
  Ezetimibe does not increase circulating PCSK9 concentrations while simvastatin does. When added to simvastatin, ezetimibe does not cause an incremental increase in PCSK9 concentrations. Changes in PCSK9 concentrations are tightly regulated and mainly influenced by baseline PCSK9 levels and changes in LDL cholesterol.
  
  
  BACKGROUND
  ClinicalTrials.gov NCT00317993.
authors.affiliation: Charité University Medicine Berlin, Evangelical Geriatrics Center Berlin (EGZB), Berlin, Germany. heiner.berthold@charite.de
authors.forename: Heiner K
authors.initials: HK
authors.lastname: Berthold
authors.forename: Nabil G
authors.initials: NG
authors.lastname: Seidah
authors.forename: Suzanne
authors.initials: S
authors.lastname: Benjannet
authors.forename: Ioanna
authors.initials: I
authors.lastname: Gouni-Berthold
mesh_terms: D000328:Adult; D001384:Azetidines / Q000494:pharmacology*; D008078:Cholesterol, LDL / Q000097:blood; D000069438:Ezetimibe; D006801:Humans; D008297:Male; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases / Q000097:blood*; D012697:Serine Endopeptidases / Q000097:blood*; D019821:Simvastatin / Q000494:pharmacology*; D015854:Up-Regulation / Q000187:drug effects*
chemical_list: D001384:Azetidines; D008078:Cholesterol, LDL; D019821:Simvastatin; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases; D000069438:Ezetimibe
references.citation: Clin Exp Pharmacol Physiol. 2010 Apr;37(4):471-6
references.pmid: 19930424
references.citation: Clin Ther. 2001 Aug;23(8):1209-30
references.pmid: 11558859
references.citation: Am J Epidemiol. 1990 Jan;131(1):20-31
references.pmid: 2293749
references.citation: Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1454-9
references.pmid: 15178557
references.citation: Circulation. 2008 Jul 22;118(4):355-62
references.pmid: 18559695
references.citation: Nutr Metab Cardiovasc Dis. 2011 Nov;21(11):835-43
references.pmid: 21943799
references.citation: Am J Med. 2001 Apr 1;110(5):352-60
references.pmid: 11286949
references.citation: J Lipid Res. 2008 Feb;49(2):394-8
references.pmid: 18033751
references.citation: Atherosclerosis. 2008 May;198(1):198-207
references.pmid: 17980884
references.citation: Mol Nutr Food Res. 2012 Jul;56(7):1160-72
references.pmid: 22610960
references.citation: Traffic. 2007 Jun;8(6):718-32
references.pmid: 17461796
references.citation: Eur Heart J. 2010 Jul;31(13):1633-9
references.pmid: 20525999
references.citation: Pharmacology. 2012;89(1-2):74-82
references.pmid: 22343316
references.citation: Lipids Health Dis. 2006 Aug 15;5:22
references.pmid: 16911794
references.citation: J Am Coll Cardiol. 2012 May 15;59(20):1778-84
references.pmid: 22575316
references.citation: Clin Endocrinol (Oxf). 2008 Apr;68(4):536-41
references.pmid: 17973945
references.citation: N Engl J Med. 2006 Mar 23;354(12):1264-72
references.pmid: 16554528
references.citation: J Lipid Res. 2010 Jan;51(1):140-9
references.pmid: 19571328
references.citation: Trans Am Clin Climatol Assoc. 2009;120:163-73
references.pmid: 19768174
references.citation: Drug Saf. 2006;29(8):703-12
references.pmid: 16872244
references.citation: Nat Rev Drug Discov. 2012 May;11(5):367-83
references.pmid: 22679642
references.citation: Arterioscler Thromb Vasc Biol. 2006 May;26(5):1094-100
references.pmid: 16424354
references.citation: J Lipid Res. 2010 Sep;51(9):2714-21
references.pmid: 20525997
references.citation: J Clin Invest. 1994 May;93(5):2168-74
references.pmid: 8182149
references.citation: Lipids Health Dis. 2011 Feb 28;10:38
references.pmid: 21352602
references.citation: J Clin Endocrinol Metab. 2010 Feb;95(2):800-9
references.pmid: 19965915
references.citation: Physiol Genomics. 2010 Mar 3;41(1):42-52
references.pmid: 20009009
references.citation: Clin Chem. 2012 Jan;58(1):183-9
references.pmid: 22065156
references.citation: J Pharmacogenomics Pharmacoproteomics. 2012 Mar 16;S5:
references.pmid: 23264882
references.citation: Expert Opin Ther Targets. 2009 Jan;13(1):19-28
references.pmid: 19063703
references.citation: Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2654-60
references.pmid: 16224054
references.citation: Nutr Res. 2011 Sep;31(9):659-64
references.pmid: 22024489